The digital musculoskeletal-care company is expanding into gut health — a huge, underserved market — with plans for one combined app in 2027.
A UConn project won a $500,000 grant to make low-cost DHA powder from microalgae grown on brewery waste, targeting a key nutrient gap for pregnant women.
Edinburgh and Bristol researchers traced disc degeneration to a collagen defect and mineral buildup — and found existing drugs could slow it, hinting at alternatives to surgery.
The deal adds gildeuretinol, a modified vitamin A in Phase 3 for Stargardt disease, to Tarsus — a program championed by Vertex founder Josh Boger.
Backed by Bezos and Gates funds, the company’s fungal-genome platform yielded LIFE-001, a long-acting drug that suppresses transplant rejection while sparing the brain.
The orexin-boosting pill treats the underlying biology of narcolepsy type 1 — keeping patients awake and curbing cataplexy — and opens a lucrative new drug class.
BMS will deploy Schrödinger’s new AI “co-scientist” and synthesis-planning tools alongside physics-based simulation to speed molecular design.
Replimune’s oncolytic virus, given with nivolumab, won accelerated approval for melanoma that has progressed on immunotherapy — after two prior rejections.
Gladstone scientists engineered human interneurons from stem cells and used them to repair the nerve pathways that control breathing after spinal cord injury.
Stanford and UCSF researchers showed the Alzheimer’s protein tau invades mitochondria and forces electrons to flow backward, and an experimental drug blocked the damage.
The cardiac-myosin inhibitor developer priced one of the year’s larger biotech IPOs to fund BHB-1893, a would-be rival to Bristol Myers’ Camzyos for a serious heart-muscle disease.
In a 170-patient, placebo-controlled study, dronabinol cut nightmare severity more than placebo — though it did not clearly reduce overall PTSD or depression.